Venom-Induced Inflammation:
Snake venoms (specifically from families like Viperidae and Elapidae) trigger a strong inflammatory response involving the complement system and the release of pro-inflammatory cytokines such as IL-1β, IL-6, and IL-8.
Chemokine Release: Studies indicate that venom can induce the production of chemokines such as CCL2 (MCP-1) and CCL5 (RANTES).
Venomous snakebites cause an estimated 81,000 to 138,000 deaths per year worldwide, with over 125,000 fatalities, primarily in rural, tropical areas of Asia and Sub-Saharan Africa.
Beyond deaths, these bites lead to roughly 400,000 permanent disabilities annually, including amputations, chronic infections, and severe psychological trauma.
Nature
+4
Approximately 4.5 to 5.4 million people are bitten by snakes annually, and 1.8 to 2.7 million of these bites involve venom (envenomation).
____
LL profile & having reduced Tecentriq toxicity to almost nonexistent, is a potentially "paradim shift", reaching into many industries beyond tumors.
Many drug repurposing trials, is possibly an unlimited horizon for Leronlimab.
Snake venoms (specifically from families like Viperidae and Elapidae) trigger a strong inflammatory response involving the complement system and the release of pro-inflammatory cytokines such as IL-1β, IL-6, and IL-8.
Chemokine Release: Studies indicate that venom can induce the production of chemokines such as CCL2 (MCP-1) and CCL5 (RANTES).
Venomous snakebites cause an estimated 81,000 to 138,000 deaths per year worldwide, with over 125,000 fatalities, primarily in rural, tropical areas of Asia and Sub-Saharan Africa.
Beyond deaths, these bites lead to roughly 400,000 permanent disabilities annually, including amputations, chronic infections, and severe psychological trauma.
Nature
+4
Approximately 4.5 to 5.4 million people are bitten by snakes annually, and 1.8 to 2.7 million of these bites involve venom (envenomation).
____
LL profile & having reduced Tecentriq toxicity to almost nonexistent, is a potentially "paradim shift", reaching into many industries beyond tumors.
Many drug repurposing trials, is possibly an unlimited horizon for Leronlimab.
10
